Загрузка...
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
[Image: see text] Inhibition of mutant IDH1 is being evaluated clinically as a promising treatment option for various cancers with hotspot mutation at Arg(132). Having identified an allosteric, induced pocket of IDH1(R132H), we have explored 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibito...
Сохранить в:
| Опубликовано в: : | ACS Med Chem Lett |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Chemical
Society
2017
|
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5641959/ https://ncbi.nlm.nih.gov/pubmed/29057061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.7b00342 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|